The initial public offer (IPO) of Jamnagar-based Winsol Engineering has been receiving a bumper response from investors with ...

CTX340™ and CTX450™ utilize LNP-based delivery of CRISPR/Cas9 gene editing cargo to the liver, targeting angiotensinogen (AGT ...

U.S. FDA Approval of Abecma for Triple-Class Exposed Relapsed or Refractory Multiple Myeloma After Two Prior Lines of Therapy ...

This is particularly valuable in indications such as TSC, where approximately 25% of patients suffer from highly refractory epilepsy.” Dr. Hulihan added, “We have enrolled 100 patients in the RAISE ...

FIRST QUARTER 2024 AND RECENT ACHIEVEMENTS Cemsidomide (CFT7455): Cemsidomide (CFT7455) is an oral degrader of IKZF1/3 for the potential treatment of relapsed/refractory (R/R) multiple myeloma (MM) ...

Additionally, by the end of this year we plan to present initial dose escalation data for CB-011 in relapsed or refractory multiple myeloma.” Clinical highlights CB-010, a clinical-stage allogeneic ...

Darzalex (daratumumab) is a monoclonal antibody drug currently approved for both refractory and new multiple myeloma. It’s available in intravenous and subcutaneous formulations.

De Grey Mining has prepped itself for debt financing at its mega Hemi gold mine after announcing a mammoth $600m equity raising.

ADC Therapeutics is positioning Zynlonta for a label expansion with new Phase II data showing that the treatment can elicit high rates of complete response in patients with relapsed or refractory ...

Garo Armen; Chairman of the Board, Chief Executive Officer, Co-Founder; Agenus Inc Steven O'Day; Chief Medical Officer; Agenus Inc Robin Taylor; Chief Commercial Officer; Agenus Inc Christine Klaskin; ...

And in contrast, ATH. one 38, depending on which read-out you use, it's very similar potency, refractory CAR T K kind of the clinical exposures and doses that we have, clients use it have you and what ...

On April 25, 2024, Y-mAbs announced several abstracts to be presented at the 2024 American Society of Clinical Oncology (“ASCO”) Annual Meeting taking place May 31 through June 4, 2024, in Chicago, IL ...